Emergent Bio Solutions, Inc.
GPTKB entity
Statements (28)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Bio_Thrax
|
gptkbp:acquisition |
gptkb:Cangene_Corporation
gptkb:Pax_Vax,_Inc. |
gptkbp:ceo |
gptkb:Robert_G._Kramer_Jr.
|
gptkbp:employees |
~1,500
|
gptkbp:focus |
public health
infectious diseases biodefense |
gptkbp:founded |
gptkb:1998
|
gptkbp:founder |
gptkb:Fuad_El-Hibri
|
gptkbp:headquarters |
gptkb:Gaithersburg,_Maryland
|
https://www.w3.org/2000/01/rdf-schema#label |
Emergent Bio Solutions, Inc.
|
gptkbp:industry |
gptkb:drug
|
gptkbp:location |
gptkb:United_States
gptkb:Native_American_tribe |
gptkbp:partnership |
gptkb:U._S._government
various pharmaceutical companies |
gptkbp:products |
vaccines
therapeutics |
gptkbp:revenue |
$1.1 billion (2020)
|
gptkbp:services |
contract manufacturing
biodefense products |
gptkbp:subsidiary |
gptkb:Emergent_Bio_Defense,_Inc.
gptkb:Emergent_Vaccines,_Inc. |
gptkbp:symbol |
EBS
|
gptkbp:website |
www.emergentbiosolutions.com
|